REFERENCES
1. Hill LM, Breckle R, Thomas ML, Fries JK. Polyhydramnios: ultrasonically detected prevalence and neonatal outcome. Obstet Gynecol 1987;69:21-5.
2. Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol 1999;94:773-7.
3. Bauserman M, Nathan R, Lokangaka A, et al. Polyhydramnios among women in a cluster-randomized trial of ultrasound during prenatal care within five low and low-middle income countries: a secondary analysis of the first look study. BMC Pregnancy Childbirth 2019;19:258.
4. Dashe JS, McIntire DD, Ramus RM, Santos-Ramos R, Twickler DM. Hydramnios: anomaly prevalence and sonographic detection. Obstet Gynecol 2002;100:134-9.
5. Guibourdenche J, Bonnet-Serrano F, Younes Chaouch L, et al. Amniotic aaquaporins (AQP) in normal and pathological pregnancies: interest in polyhydramnios. Reprod Sci 2021;28:2929-38.
6. Abele H, Starz S, Hoopmann M, Yazdi B, Rall K, Kagan KO. Idiopathic polyhydramnios and postnatal abnormalities. Fetal Diagn Ther 2012;32:251-5.
7. Touboul C, Boileau P, Picone O, Foix-l’Hélias L, Frydman R, Senat M. Outcome of children born out of pregnancies complicated by unexplained polyhydramnios. BJOG 2007;114:489-92.
8. Konrad M, Nijenhuis T, Ariceta G, et al. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney Int 2021;99:324-35.
9. Kömhoff M, Laghmani K. Pathophysiology of antenatal Bartter’s syndrome. Curr Opin Nephrol Hypertens 2017;26:419-25.
10. Laghmani K, Beck BB, Yang SS, et al. Polyhydramnios, transient antenatal Bartter’S syndrome, and MAGED2 mutations. N Engl J Med 2016;374:1853-63.
11. Legrand A, Treard C, Roncelin I, et al. Prevalence of novel MAGED2 mutations in antenatal bartter syndrome. Clin J Am Soc Nephrol 2018;13:242-50.
12. Reinalter S, Devlieger H, Proesmans W. Neonatal bartter syndrome: spontaneous resolution of all signs and symptoms. Pediatr Nephrol 1998;12:186-8.
13. Meyer M, Berrios M, Lo C. Transient antenatal Bartter’S syndrome: a case report. Front Pediatr 2018;6:51.
14. Yang K, Huo X, Zhang Y, et al. Genetic analysis of a pedigree affected with Bartter’s syndrome. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2019;36:701-3.
15. Takemori S, Tanigaki S, Nozu K, et al. Prenatal diagnosis of MAGED2 gene mutation causing transient antenatal Bartter syndrome. Eur J Med Genet 2021;64:104308.
16. Ma M, Zhang M, Zhou Y, et al. A novel MAGED2 variant in a Chinese preterm newborn with transient antenatal Bartter’s syndrome with 4 years follow-up. BMC Nephrol 2021;22:408.
17. Arthuis CJ, Nizon M, Kömhoff M, et al. A step towards precision medicine in management of severe transient polyhydramnios: MAGED2 variant. J Obstet Gynaecol 2019;39:395-7.
18. Wu X, Huang L, Luo C, Liu Y, Niu J. A case report and literature review of a novel mutation in the MAGED2 gene of a patient with severe transient polyhydramnios. Front Pediatr 2021;9:778814.
19. Alajjuri OA, Samaha ME, Honemeyer U, Mohammed G, Mousa NA. Balancing benefits and risks of indomethacin in the management of antenatal bartter syndrome: a case report. Front Med 2022;9:870503.
20. Konrad M, Leonhardt A, Hensen P, Seyberth HW, Köckerling A. Prenatal and postnatal management of hyperprostaglandin E syndrome after genetic diagnosis from amniocytes. Pediatrics 1999;103:678-83.
21. Tourne G, Collet F, Varlet MN, et al. Prenatal Bartter’s syndrome. report of two cases. J Gynecol Obstet Biol Reprod 2003;32:751-4.
22. Reddy UM, Abuhamad AZ, Levine D, et al. Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging workshop. Obstet Gynecol 2014;123:1070-82.
23. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24.
24. Karahanoglu E, Ozdemirci S, Esinler D, et al. Intrapartum, postpartum characteristics and early neonatal outcomes of idiopathic polyhydramnios. J Obstet Gynaecol 2016;36:710-4.
25. Allaf B, Dreux S, Schmitz T, et al. Amniotic fluid biochemistry in isolated polyhydramnios: a series of 464 cases. Prenat Diagn 2015;35:1331-5.
26. Bhat YR, Vinayaka G, Vani R, Prashanth KA, Sreelakshmi K. Antenatal Bartter syndrome: a rare cause of unexplained severe polyhydramnios. Ann Trop Paediatr 2011;31:153-7.
27. Dane B, Dane C, Aksoy F, Cetin A, Yayla M. Antenatal Bartter syndrome: analysis of two cases with placental findings. Fetal Pediatr Pathol 2010;29:121-6.
29. Wilson A, Hodgetts-Morton VA, Marson EJ, et al. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev 2022;8:CD014978.
30. Kömhoff M, Laghmani K. MAGED2: a novel form of antenatal Bartter’s syndrome. Curr Opin Nephrol Hypertens 2018;27:323-8.
